Protein tyrosine phosphatase 1B in metabolic diseases and drug development
Nature Reviews Endocrinology, Published online: 22 March 2024; doi:10.1038/s41574-024-00965-1This Review summarizes cellular processes and regulation of protein tyrosine phosphatase 1B (PTP1B), discussing evidence from in vivo preclinical and human studies. PTP1B inhibitors, which are being developed for type 2 diabetes mellitus, obesity, rare diseases (such as Rett syndrome) and some cancers, are also discussed.
Source: Nature Reviews Endocrinology - Category: Endocrinology Authors: Mirela Delibegovi ć Sergio Dall ’Angelo Ruta Dekeryte Source Type: research
More News: Cancer | Cancer & Oncology | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Obesity | Rare Diseases | Rett Syndrome | Study